Type 1 Diabetes Market Increasing Demand, Growth Analysis and Future Outlook by 2031

The global type 1 diabetes treatment market is anticipated to grow at a considerable CAGR of 7.8% during the forecast period. The market growth is mainly attributed to the growing number of type 1 diabetes patients across the globe especially in emerging economies like India and China. According to the IDF (International Diabetes Federation), in 2020, there were 463 million people in the globe who had diabetes and Type 1 diabetes accounts for around 7-10% of diabetes cases globally. It is most commonly seen in persons older than 45 years. However, due to the rising prevalence of several chronic diseases associated with diabetes, it is also increasingly seen in children, adolescents, and younger adults. Moreover, the increase in the geriatric population, rising demand for non-invasive monitoring devices, and changing lifestyles of people are some of the other factors that drive the growth of the market.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/type-1-diabetes-market

In addition to this, initiatives are taken by government organizations to control the rising prevalence of diabetes also drives the growth of the market. For instance, Novo Nordisk is working with the Chinese government for strengthening the healthcare system in the country. Under the Cities Changing Diabetes partnership sponsored by Novo Nordisk, six Chinese cities, including Shanghai, Beijing, Tianjin, Xiamen, Chongqing, and Hangzhou, have linked with the Cities Changing Diabetes partnership. Besides, In February 2019, the directorate of health services (government of goa) and Sanofi India join hands to reduce the diabetes burden on the state. The partnership is for 3 years intended to create awareness of diabetes and its management for a better quality of life. Although, in March 2019, AstraZeneca's Forxiga got approved in Europe for type-1 diabetes as an adjunct to insulin in patients with a BMI ? 27 kg/m2.

Global Type 1 Diabetes Treatment Market Report Segment

By Insulin Analog

• Rapid-Acting
• Long-Acting
• Premix

By Drug Class

• Insulin
• Non-Insulin

By Devices

• Insulin Pumps
• Insulin Pen
• Blood Glucose Meters
• Others

A full report of Type 1 Diabetes Market is available at: https://www.omrglobal.com/industry-reports/type-1-diabetes-market

Type 1 Diabetes Market- Segment by Region

North America

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa
• Latin America

Company Profiles

• Abbott Laboratories
• AstraZeneca, PLC
• Hoffmann-La Roche Ltd
• Eli Lilly and Co.
• Astellas Pharma Inc.
• Becton, Dickinson and Co.
• Boehringer Ingelheim International GmbH.
• Bristol-Myers Squibb
• Dexcom, Inc.

Reasons to Buying From us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.


Visit more report at

https://www.linkedin.com/pulse/scaffold-technology-market-size-trends-latest-arti-vishwakarma-mlsof/

https://www.linkedin.com/pulse/aesthetic-threads-market-increasing-demand-growth-2031-vishwakarma-pyg5f

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.